(19)
(11) EP 2 965 763 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.08.2018 Bulletin 2018/33

(45) Mention of the grant of the patent:
06.06.2018 Bulletin 2018/23

(21) Application number: 15166498.4

(22) Date of filing: 12.04.2010
(51) International Patent Classification (IPC): 
A61K 35/74(2015.01)
A61K 31/436(2006.01)
A61K 31/047(2006.01)
A61K 36/45(2006.01)
A61K 33/06(2006.01)
A61K 31/105(2006.01)
A61K 31/4375(2006.01)
A61K 31/573(2006.01)
A61K 31/375(2006.01)
A61K 31/015(2006.01)
A61K 31/122(2006.01)
 G01N 33/53(2006.01)
A61K 31/352(2006.01)
A61K 31/01(2006.01)
A61K 36/87(2006.01)
A61K 31/26(2006.01)
A61K 31/155(2006.01)
A61K 38/22(2006.01)
A61K 31/4709(2006.01)
A61K 31/355(2006.01)
A61K 31/385(2006.01)

(54)

ANTI-AGING AGENTS

ANTI-AGING-MITTEL

AGENTS ANTI-VIEILLISSEMENT

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 10.04.2009 US 168335 P
10.04.2009 US 168311 P

(43) Date of publication of application:
13.01.2016 Bulletin 2016/02

(62) Application number of the earlier application in accordance with Art. 76 EPC:
10762568.3 / 2416792

(73) Proprietor: Qi, Haiyan
Dayton, NJ 10980 (US)

(72) Inventor:
  • Qi, Haiyan
    Dayton, NJ 10980 (US)

(74) Representative: Schlief, Thomas P. 
Canzler & Bergmeier Patentanwälte Partnerschaft mbB Friedrich-Ebert-Straße 84
85055 Ingolstadt
85055 Ingolstadt (DE)


(56) References cited: : 
EP-A1- 0 532 862
WO-A2-2008/022256
 WO-A1-2008/109163
US-A1- 2008 181 927
   
  • TSANG CHI KWAN ET AL: "Targeting mammalian target of rapamycin (mTOR) for health and diseases", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 12, no. 3-4, 1 February 2007 (2007-02-01), pages 112-124, XP002519471, ISSN: 1359-6446, DOI: 10.1016/J.DRUDIS.2006.12.008 [retrieved on 2006-12-15]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).